← Back to headlines
Blackstone Commits $400 Million with Teva for Duvakitug Clinical Development
Blackstone (BX) has committed $400 million in partnership with Teva Pharmaceutical Industries to advance the clinical development of Duvakitug.
13 Mar, 17:23 — 13 Mar, 17:23
Sources
Showing 1 of 1 sources
